A Houston founder and small-space expert founded TAXA Outdoors to create better campers than what was in the market. Now, amid the pandemic, he's seen sales skyrocket. Photo courtesy of TAXA Outdoors

In 2014 Garrett Finney, a former senior architect at the Habitability Design Center at NASA, brought his expertise in what he describes as "advocating for human presence living in a machine" to the outdoors market.

After being less-than enchanted by the current RV and camper offerings, the Houstonian developed a new series of adventure vehicles that could safely and effectively get its users off-grid — even if still Earth-bound — under the company he dubbed TAXA Outdoors.

The vehicles would follow much of the same standards that Finney worked under at NASA, in which every scenario and square inch would be closely considered in the smartly designed spaces. And rather that designing the habitats for style alone, function and storage space for essential gear took precedence. According to Finney, the habitat was to be considered a form of useful adventure equipment in its own right.

"Ceilings should be useful. They're not just for putting lights on," he says. "Even when there's gravity that's true."

Today TAXA offers four models of what they call "mobile human habitats" that can be towed behind a vehicle and sleep three to four adults, ranging from about $11,000 to $50,000 in price.

TAXA's mobile human habitats range in size and price. Photo courtesy of TAXA Outdoors

And amid the pandemic — where people were looking for a safe way to escape their homes and get outside — the TAXA habitats were flying off the shelves, attracting buyers in Texas, but mainly those in Colorado, California, and other nature-filled areas.

"January, was looking really good — like the break out year. And then the pandemic was a huge red flag all around the world," Finney says. "[But] we and all our potential customers realized that going camping was the bet. They were with their family, they were getting outside, they were achieving sanity having fun and creating memories."

According to TAXA President Divya Brown, the company produced a record 430 habitats in 2020. But it still wasn't enough to match the number of orders coming in.

"We had we had almost a year and a half worth of backlog at the old facility, which we've never experienced before," Brown says.

To keep up with demand, the company moved into a 70,000-square-foot space off of U.S. 290 that now allows multiple operations lines, as well as a showroom for their vehicles and enough room for their staff, which tripled in size from 25 to 75 employees since the onset of the pandemic.

The first priority at the new facility is to make up the backlog they took on in 2020. Next they hope to produce more than 1,000 habitats by the end of 2021 and 3,000 in the coming years.

"It's a pretty significant jump for us," Brown says. "We really believe there's a huge market for this."

With the new facility, the TAXA team hopes to catch up with the explosive sales growth. Photo courtesy of TAXA Outdoors

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.